Common Contracts
18 similar Underwriting Agreement contracts by GreenSky, Inc., Idera Pharmaceuticals, Inc., Maiden Holdings, Ltd., others
Entrada Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 8th, 2021 • Entrada Therapeutics, Inc. • Pharmaceutical preparations • New York
Entrada Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as Representatives, an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Stewart Information Services Corporation 2,631,600 Shares Common Stock, Par Value $1.00 per Share Underwriting AgreementUnderwriting Agreement • August 17th, 2020 • Stewart Information Services Corp • Title insurance • New York
The primary purpose of our professional engagement was not to establish or confirm factual matters or financial, accounting or quantitative information. Furthermore, many determinations involved in the preparation of the Registration Statement, the Disclosure Package and the Prospectus are of a wholly or partially non-legal character or relate to legal matters outside the scope of our opinion separately delivered to you today in respect of certain matters under the laws of the State of New York, the federal laws of the United States of America and the General Corporation Law of the State of Delaware. As a result, we are not passing upon, and do not assume any responsibility for, the accuracy, completeness or fairness of the statements contained in the Registration Statement, the Disclosure Package or the Prospectus, and we have not ourselves checked the accuracy, completeness or fairness of, or otherwise verified, the information furnished in such documents (except to the extent expres
Underwriting AgreementUnderwriting Agreement • January 27th, 2020 • Elanco Animal Health Inc • Pharmaceutical preparations • New York
Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 22,694,732 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,269,473 additional shares (the “Optional Shares”) of common stock, no par value (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Underwriting AgreementUnderwriting Agreement • May 13th, 2019 • BICYCLE THERAPEUTICS LTD • Pharmaceutical preparations
Bicycle Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), and in the manner contemplated by the Agreement, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representatives”) an aggregate of [·] American Depositary Shares representing [·] Ordinary Shares nominal value £0.01 per share (the “Ordinary Shares”) and, at the election of the Underwriters, up to [·] additional American Depositary Shares representing [·] Ordinary Shares. The aggregate of [·] American Depositary Shares representing [·] Ordinary Shares to be sold by the Company is herein called the “Firm ADSs”, and the aggregate of [·] American Depositary Shares representing [·] additional Ordinary Shares to be sold by the Company is called the “Optional ADSs”. The Firm ADSs and the Optional
CytomX Therapeutics, Inc. 5,102,041 Shares of Common Stock $0.00001 par value Underwriting AgreementUnderwriting Agreement • July 17th, 2018 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (the “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 5,102,041 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 765,306 additional shares (the “Optional Shares”) of Common Stock of the Company, par value $0.00001 per share (the “Stock”) (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
GreenSky, Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • May 29th, 2018 • GreenSky, Inc. • Services-business services, nec • New York
GreenSky, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 38,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 5,700,000 additional shares (the “Optional Shares”) of Class A common stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
GreenSky, Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • May 14th, 2018 • GreenSky, Inc. • Services-business services, nec • New York
GreenSky, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Class A common stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Idera Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 26th, 2017 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 33,333,334 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 5,000,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
KMG Chemicals, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • October 20th, 2017 • KMG Chemicals Inc • Chemicals & allied products • New York
KMG Chemicals, Inc., a Texas corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 450,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.01 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively referred to as the “Shares”).
Maiden Holdings, Ltd. Underwriting AgreementUnderwriting Agreement • June 15th, 2017 • Maiden Holdings, Ltd. • Fire, marine & casualty insurance • New York
Maiden Holdings Ltd., an exempted company incorporated in Bermuda (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (collectively, the “Underwriters”, which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. LLC and UBS Securities LLC are acting as representatives (in such capacity, the “Representatives”), 6,000,000 shares (the "Shares") in the aggregate of 6.700% Non-Cumulative Preference Shares, Series D (the “Preference Shares”).
Underwriting AgreementUnderwriting Agreement • March 31st, 2017 • STORE CAPITAL Corp • Real estate investment trusts • New York
STORE Capital Corporation, a Maryland corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (collectively, the “Underwriters,” and, individually, an “Underwriter”), for whom you are acting as representatives (in such capacity, the “Representatives”), an aggregate of 8,650,000 shares (the “Firm Shares”), and, at the election of the Underwriters, up to 1,297,500 additional shares (the “Optional Shares”), of Common Stock, $0.01 par value per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
Idera Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • February 13th, 2015 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 20,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 3,000,000 additional shares (the “Optional Shares”) of Common Stock, par value $0.001 (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Underwriting AgreementUnderwriting Agreement • August 29th, 2012 • Maiden Holdings, Ltd. • Fire, marine & casualty insurance • New York
Maiden Holdings Ltd., an exempted company incorporated in Bermuda (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (collectively, the “Underwriters”, which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are acting as representative (in such capacity, the “Representatives”), 6,000,000 shares (the "Shares") in the aggregate of 8.25% Non-Cumulative Preference Shares, Series A (the “Preference Shares”).
TriMas Corporation Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • May 8th, 2012 • Trimas Corp • Metal forgings & stampings • New York
TriMas Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representatives”) an aggregate of 4,000,000 shares and, at the election of the Underwriters, up to 600,000 additional shares of Common Stock, par value $0.01 per share (“Stock”) of the Company. The aggregate of 4,000,000 shares to be sold by the Company is herein called the “Firm Shares” and the aggregate of 600,000 additional shares to be sold by the Company is herein called the “Optional Shares”. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
GCT Semiconductor, Inc. Common Stock, par value $0.001 per share Underwriting AgreementUnderwriting Agreement • February 15th, 2012 • GCT Semiconductor Inc • Semiconductors & related devices • New York
GCT Semiconductor, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [ ] additional shares (the “Optional Shares”) of Common Stock (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
ContractUnderwriting Agreement • July 30th, 2010 • Glimcher Realty Trust • Real estate investment trusts • New York
1,481,481 Shares Orrstown Financial Services, Inc. Common Stock no stated par value Underwriting AgreementUnderwriting Agreement • March 24th, 2010 • Orrstown Financial Services Inc • State commercial banks • New York
Orrstown Financial Services, Inc., a Pennsylvania corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Sandler O’Neill & Partners, L.P. (“Sandler O’Neill” or an “Underwriter”) and each of the other underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 11 hereof), for whom Sandler O’Neill is acting as representative (in such capacity, the “Representative”) with respect to (i) the sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of an aggregate of 1,481,481 shares of common stock, no par value, of the Company (the “Stock”), as set forth in Schedule I hereto (the “Firm Shares”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2 hereof to purchase all or any part of 222,222 additional shares of common st
Underwriting AgreementUnderwriting Agreement • June 10th, 2009 • Satcon Technology Corp • Semiconductors & related devices • New York
Satcon Technology Corporation, a Delaware corporation (“Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,557,692 shares of common stock, par value $0.01 per share (“Stock”), of the Company, and, at the election of the Underwriters, up to 2,333,654 additional shares of Stock. The aggregate of 15,557,692 shares to be sold by the Company is herein called the “Firm Shares” and the aggregate of 2,333,654 additional shares to be sold by the Company is herein called the “Optional Shares”. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
